EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Zurückgezogene Publikation

RETRACTED: Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study

Mohammad Saleh Shahri, Setayesh Sadeghi, Delara Hazegh Fetratjoo, Hamed Hosseini, Mohammad Amin Ghobadi, Seyyedeh Maryam Afshani, Reihaneh Mirhassani, Kimiya Gohari, Forugh Havasi, Amirhossein Abdolghaffari, Behnaz Hedayatjoo, Mostafa Ghanei

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112214 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Mohammad Saleh Shahri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Antibodies, Viral, Vaccines, Synthetic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Iran Food and Drug Administration, Tehran University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the face of global health threats, there is a growing demand for vaccines that can be manufactured on a large scale within compressed timeline. This study responds to this imperative by delving into the evaluation of FluGuard, a novel recombinant influenza vaccine developed by Nivad Pharmed Salamat Company in Iran. Positioned as a phase 3 extension, the research aimed to evaluate the safety and immunogenicity of FluGuard in volunteers aged 18 and above. The study was conducted as a single-center, open-label clinical trial. All eligible volunteers received FluGuard (2021-2022 Formula) on day 0. Safety assessments occurred at days 1, 4, 7, 14, 28 and 42 post-vaccination. Immunogenicity was measured through seroconversion, seroprotection, and geometric mean titer fold increase in subgroups of 250 volunteers. Among the 4,260 volunteers were screened and assessed for eligibility, 1000 were enrolled. At day 28 post-vaccination, seroconversion rates for A/H1N1, A/H3N2, B/Yamagata, B/Victoria were 53.4 % [95 %CI: 46.7-60], 57.7 % [95 %CI: 51.1-64.3], 54.3 % [95 %CI: 47.7-60.9], and 36.2 % [95 %CI: 29.8-42.6], respectively in volunteers 18 years and above. The most common solicited adverse events were pain at the injection site, malaise, and headache. No suspected unexpected adverse events and adverse events of special interest occurred during the study period. Our findings suggested that FluGuard® exhibits a desirable safety profile and provides sufficient immunogenicity against influenza virus types A and B. However, extended studies are warranted to assess the long-term protective efficacy. Trial Registration: The study protocol was accepted by Iranian registry of clinical trial; https://www.irct.ir; IRCT20201104049265N2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanAntibodies, ViralVaccines, SyntheticHumansAdultMaleFemaleMiddle AgedYoung AdultAdolescentBaculoviridaeImmunogenicity, VaccineInfluenza A Virus, H1N1 SubtypeInfluenza B virusVaccinationIran

Stichwörter der Autor:innen

Adverse eventFluGuardImmunogenicityInfluenza SafetyInfluenza TrialRecombinant Influenza Vaccine

Substanzen

Influenza VaccinesAntibodies, ViralVaccines, Synthetic

Autor:innen und Institutionen

  • Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran; Nivad Pharmed Salamat, Biotechnology Research Center, Tehran, Iran.
  • Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Nivad Pharmed Salamat, Biotechnology Research Center, Tehran, Iran; Department of Chemistry, Faculty of Sciences, University of Kurdistan, Sanandaj, Iran.

Förderung

  • Iran Food and Drug Administration
  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Shahri, M. S., Sadeghi, S., Hazegh Fetratjoo, D., Hosseini, H., Amin Ghobadi, M., Afshani, S. M., Mirhassani, R., Gohari, K., Havasi, F., Abdolghaffari, A., Hedayatjoo, B., & Ghanei, M. (2024). RETRACTED: Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112214

Vancouver

Shahri MS, Sadeghi S, Hazegh Fetratjoo D, Hosseini H, Amin Ghobadi M, Afshani SM, et al. RETRACTED: Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112214

BibTeX
@article{Shahri2024,
  author = {Shahri, Mohammad Saleh and Sadeghi, Setayesh and Hazegh Fetratjoo, Delara and Hosseini, Hamed and Amin Ghobadi, Mohammad and Afshani, Seyyedeh Maryam and Mirhassani, Reihaneh and Gohari, Kimiya and Havasi, Forugh and Abdolghaffari, Amirhossein and Hedayatjoo, Behnaz and Ghanei, Mostafa},
  title = {RETRACTED: Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112214}
}
Kostenlos starten →